# Broad-Spectrum Antagonists For Editors (B-SAFE)

Source: https://welltoldgrants.com/grants/hr001124s0032-broad-spectrum-antagonists-for-editors-b-safe/  
Official notice: https://www.grants.gov/search-results-detail/354978

> DARPA - Biological Technologies Office offered grants to the applicants described in the notice. Applications closed on August 12, 2024.

| Field | Value |
|---|---|
| Opportunity number | HR001124S0032 |
| Agency | DARPA - Biological Technologies Office |
| Status | Forecast |
| Deadline | August 12, 2024 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 12.910 |

## Who can apply

- Others (see text field entitled "Additional Information on Eligibility" for clarification)

All responsible sources capable of satisfying the Government's needs may submit a proposal that shall be considered by DARPA. See the Eligibility Information section of the BAA for more information.

## What the grant funds

The Defense Advanced Research Projects Agency (DARPA) is soliciting innovative proposals to identify and optimize novel molecules that exhibit inhibitory effects on Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-CRISPR associated proteins (CRISPR-Cas) gene editing processes. The Broad-Spectrum Antagonists for Editors (B-SAFE) program is explicitly seeking transformative approaches enabling the discovery or design of novel inhibitors of gene editing technologies with enhanced activity, utility, and breadth of coverage. Novel inhibitor activity will be assessed in vitro over the course of the program and a subset of top performing molecules will be selected for scale-up at quantities sufficient for testing and evaluation by Department of Defense (DoD) stakeholders. In concert, DARPA is interested in exploring methods to rapidly discover inhibitor molecules for novel gene editing technologies beyond CRISPR-Cas systems to keep pace with the rapidly advancing field and promote the safe, controlled use of these technologies. Research that generates incremental improvements to the existing state-of-the-art are specifically excluded.

## Questions people ask

### Is HR001124S0032 still open?

No. It closed on August 12, 2024. A newer notice is open: DARPARA2701, closes January 13, 2027 (67 days left).

### Who can apply for Broad-Spectrum Antagonists For Editors (B-SAFE)?

DARPA - Biological Technologies Office accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Broad-Spectrum Antagonists For Editors (B-SAFE)?

Closed August 12, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### Who has won Research and Technology Development grants before?

The largest recipients over five fiscal years were University of Southern California, Clemson University, Massachusetts Institute of Technology. The program made 739 awards worth $1.5 billion in that time.